- Home
- STAI vs NRSN Comparison
STAI vs NRSN Comparison
Compare STAI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- NRSN
- Stock Information
- Founded
- STAI 2011
- NRSN 2017
- Country
- STAI United States
- NRSN Israel
- Employees
- STAI N/A
- NRSN N/A
- Industry
- STAI
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- NRSN Health Care
- Exchange
- STAI Nasdaq
- NRSN Nasdaq
- Market Cap
- STAI 24.6M
- NRSN 26.0M
- IPO Year
- STAI N/A
- NRSN 2021
- Fundamental
- Price
- STAI $0.45
- NRSN $1.21
- Analyst Decision
- STAI
- NRSN Buy
- Analyst Count
- STAI 0
- NRSN 2
- Target Price
- STAI N/A
- NRSN $14.00
- AVG Volume (30 Days)
- STAI 2.3M
- NRSN 1.4M
- Earning Date
- STAI 09-17-2025
- NRSN 09-17-2025
- Dividend Yield
- STAI N/A
- NRSN N/A
- EPS Growth
- STAI N/A
- NRSN N/A
- EPS
- STAI N/A
- NRSN N/A
- Revenue
- STAI $907,637.00
- NRSN N/A
- Revenue This Year
- STAI N/A
- NRSN N/A
- Revenue Next Year
- STAI N/A
- NRSN N/A
- P/E Ratio
- STAI N/A
- NRSN N/A
- Revenue Growth
- STAI N/A
- NRSN N/A
- 52 Week Low
- STAI $0.35
- NRSN $0.80
- 52 Week High
- STAI $9.07
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- STAI 48.15
- NRSN 48.31
- Support Level
- STAI $0.35
- NRSN $1.14
- Resistance Level
- STAI $0.50
- NRSN $1.28
- Average True Range (ATR)
- STAI 0.04
- NRSN 0.15
- MACD
- STAI 0.02
- NRSN 0.03
- Stochastic Oscillator
- STAI 64.29
- NRSN 25.24
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.